Dr Mautner is CEO and Managing Director of ASX-listed biotech company Noxopharm Limited (ASX:NOX).
Before joining Noxopharm, Gisela has developed her career of over 20 years in leadership roles in global pharmaceutical and medical device organisations across multiple continents and therapeutic areas.
She is an international business leader with significant experience developing and launching new products and delivering successful corporate strategies in highly
competitive global markets. These skills are now being applied in the emerging area of mRNA technologies, autoimmune disease and oncology.
This experience is founded on an education at some of the world’s highest-ranking institutions, a Master of Public Health from Harvard, an MBA from the Kellogg School of Management at Northwestern University in Chicago, a PhD from Ludwig Maximilian University in Munich, and a Doctor of Medicine degree from Technical University in Munich. She is also a Graduate of the Australian Institute of Company Directors and a member of the CEO Institute.
Gisela has strong global pharmaceutical industry networks and served as President, Vice-President and Treasurer of the Australian Pharmaceutical Physicians Association (APPA; now MAPA) for many years with serving until recently as Past-President. She is also the Australian delegate for the International Federation of Associations of Pharmaceutical Physicians (IFAPP), which connects the pharmaceutical industry globally. Recently she was appointed as Chair of the Biotechnology Committee of BIO NSW, a Not-for-Profit body to promote Life Sciences across NSW.
Gisela‘s Board experience includes serving on the Noxopharm Board, as well as being a Non-Executive Board member of Nyrada Inc., a US biotechnology company listed on the ASX. She is also a Non-Executive Board member for a Not-for-Profit national sports organisation.